Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders ...Middle East

– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew...

Hence then, the article about immunic reports positive results from phase 1b clinical trial of imu 856 in celiac disease providing clinical proof of concept for new therapeutic approach to gastrointestinal disorders was published today ( Thursday 04/05/2023 - 01:33 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders )

Also on site :

• Trump administration efforts to shift blame for ICE shooting wreak havoc on Minnesota US attorney’s office
• Mizzou picks up transfer commitment from former B1G DB, 4-star recruit in 2025
• Lanes blocked in northwest suburban intersection after multi-vehicle crash